Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CBFB | Q13951 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL736438 | 0.84 | RHEB (0.32) | KDM4E | |
| SCHEMBL4956057 | 0.82 | NOS1 (0.33) | HPGDMEN1KMT2A | |
| SCHEMBL8012959 | 0.81 | PNMT (0.39) | KEAP1NFE2L2HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL10489411 | 0.81 | — | — | |
| SCHEMBL9484127 | 0.80 | CBFB (0.47) | ALDH1A1CBFBSMN1; SMN2HSD17B10MEN1 | |
| SCHEMBL29338407 | 0.80 | MIF (0.41) | SMN1; SMN2HSD17B10MCHR1MEN1KMT2A | |
| SCHEMBL9483444 | 0.78 | MCHR1 (0.48) | HPGDALDH1A1TP53ALOX15CBFB | |
| SCHEMBL7707716 | 0.78 | SLC22A6 (0.44) | HPGDALDH1A1CYP3A4TP53SMN1; SMN2 | |
| SCHEMBL5410357 | 0.78 | PIK3CB (0.33) | — | |
| SCHEMBL44289 | 0.77 | MAPT (0.33) | HPGDHSD17B10LMNAPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831387-B1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS LLC (US) | 2026-01-14 | — | — | EP | disclosed |
| CN-113750107-B | Neuroactive steroids, compositions and uses thereof | 萨奇治疗股份有限公司 | 2025-02-11 | — | — | CN | disclosed |
| US-12071453-B2 | Neuroactive steroids, compositions, and uses thereof | SAGE THERAPEUTICS, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240239836-A9 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20230279044-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | SAGE THERAPEUTICS INC (US) | 2023-09-07 | — | — | US | disclosed |
| US-11530237-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11498940-B2 | Neuroactive steroids, compositions, and uses thereof | SAGE THERAPEUTICS, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| CN-113750107-A | Neuroactive steroids, compositions and uses thereof | 萨奇治疗股份有限公司 | 2021-12-07 | — | — | CN | disclosed |
| EP-3885352-A1 | A COMPOUND, COMPOSITIONS THEREOF AND THIS COMPOUND FOR USE IN METHODS OF TREATING CNS DISORDERS | Sage Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| CN-105579043-B | Neuroactive steroids, compositions and uses thereof | 萨奇治疗股份有限公司 | 2021-09-14 | — | — | CN | disclosed |
| US-20110301170-A1 | Inhibitors of JNK | GONG LEYI (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301170-A1 | Inhibitors of JNK | GONG LEYI (US) | 2011-12-08 | — | — | US | disclosed |
| US-20050221982-A1 | Heat sensitive recording material | CIBA SPECIALTY CHEMICALS CORP. | 2005-10-06 | — | — | US | disclosed |
| US-6464901-B1 | IN AQUEOUS SYSTEMS BEING TREATED WITH A HALOGEN BIOCIDE; NONHALOGENATED, NITROGEN CONTAINING, AROMATIC COMPOUNDS; PROVIDING SUBSTITUTION FOR THE HYDROGENS OF THE BENZENE RING OF A BENZOTRIAZOLE | BL TECHNOLOGIES, INC. | 2002-10-15 | — | — | US | disclosed |
| EP-0393721-A2 | Silver halide photographic material | FUJI PHOTO FILM CO., LTD. (JP) | 1990-10-24 | — | — | EP | disclosed |
| US-4719248-A | BENZOTRIAZOLE UNSATURATED AMIDE | BAUSCH & LOMB INCORPORATED (US) | 1988-01-12 | — | — | US | disclosed |
| EP-0221630-A2 | Ultraviolet blocking agents for contact lenses | BAUSCH & LOMB INCORPORATED (US) | 1987-05-13 | — | — | EP | disclosed |
| US-4536189-A | FUEL ADDITIVE FOR GASOHOL | TEXACO INC. (US) | 1985-08-20 | — | — | US | disclosed |
| EP-0144087-A2 | Heat-developable color light-sensitive material | KONICA CORPORATION (JP) | 1985-06-12 | — | — | EP | disclosed |
| US-4376635-A | Novel gasohol or ethanol fuel composition containing as a corrosion inhibitor the reaction product of benzothiazole, formaldehyde and an N-alkyl propylene diamine | TEXACO INC. (US) | 1983-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530237-B2 | Compositions and methods for treating CNS disorders | ADRA1B, ADRA2B, ADRA1A | KEAP1 2086/4885NFE2L2 3766/4885NQO2 2023/4885 |
| US-12071453-B2 | Neuroactive steroids, compositions, and uses thereof | TACR2, OPRL1, TACR1 | KEAP1 2571/4885NFE2L2 2842/4885NQO2 1814/4885 |
| US-20240239836-A9 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | ADRB2, TACR2, CNR1 | KEAP1 2551/4885NFE2L2 2880/4885NQO2 1516/4885 |
| US-20230279044-A1 | NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF | ADRB2, TACR2, CNR1 | KEAP1 2551/4885NFE2L2 2880/4885NQO2 1516/4885 |
| US-20110301170-A1 | Inhibitors of JNK | MAPK6, MAP3K6, MAPK1 | KEAP1 570/4885NFE2L2 979/4885NQO2 1187/4885 |
| US-11498940-B2 | Neuroactive steroids, compositions, and uses thereof | TACR2, GABRA5, CNR1 | KEAP1 2904/4885NFE2L2 3055/4885NQO2 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.